{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:40:45Z","timestamp":1793356845757,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101289","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:07:21Z","timestamp":1789052841000},"page":"101289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-2019","authenticated-orcid":false,"given":"Reza","family":"Ghalehtaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4196-7981","authenticated-orcid":false,"given":"Alireza","family":"Shariati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8228-1204","authenticated-orcid":false,"given":"Taher","family":"Fanihagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8798-3278","authenticated-orcid":false,"given":"Zahra","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4169-6564","authenticated-orcid":false,"given":"Niloofar","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctro.2026.101289_bb0005","first-page":"656","article-title":"Esophageal cancer global burden profiles, trends, and contributors","volume":"21","author":"Teng","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ctro.2026.101289_bb0010","article-title":"Burden of esophageal cancer in global, regional and national regions from 1990 to 2021 and its projection until 2050: results from the GBD study 2021","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.ctro.2026.101289_bb0015","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hagen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctro.2026.101289_bb0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"issue":"Suppl. 8","key":"10.1016\/j.ctro.2026.101289_bb0025","doi-asserted-by":"crossref","first-page":"S697","DOI":"10.21037\/jtd.2017.03.159","article-title":"Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials","volume":"9","author":"Donohoe","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"10302","key":"10.1016\/j.ctro.2026.101289_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctro.2026.101289_bb0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced Esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic Esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctro.2026.101289_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.ctro.2026.101289_bb0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctro.2026.101289_bb0060","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0065","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/JS9.0000000000000816","article-title":"Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"110","author":"Xu","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ctro.2026.101289_bb0070","article-title":"The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"He","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctro.2026.101289_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.09.019","article-title":"Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer","volume":"52","author":"Lim","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctro.2026.101289_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10388-024-01097-1","article-title":"Optimizing neoadjuvant radiotherapy for locally advanced esophageal squamous cell carcinoma: a comprehensive review on the role of concomitant or sequential immune checkpoint inhibitors","volume":"22","author":"Ghalehtaki","year":"2025","journal-title":"Esophagus"},{"issue":"23","key":"10.1016\/j.ctro.2026.101289_bb0090","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/cncr.35561","article-title":"Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: a review","volume":"130","author":"Abyaneh","year":"2024","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.ctro.2026.101289_bb0095","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.ctro.2026.101289_bb0100","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung Cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112939","article-title":"Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer","volume":"141","author":"Guo","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008229","article-title":"Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial","volume":"12","author":"Jiang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04273-6","article-title":"Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial","volume":"21","author":"Yang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctro.2026.101289_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102118","article-title":"A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)","volume":"62","author":"Chen","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ctro.2026.101289_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.ctro.2026.101289_bb0130","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.21037\/jtd-23-1388","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE)","volume":"15","author":"Chen","year":"2023","journal-title":"J. Thorac. Dis."},{"issue":"7","key":"10.1016\/j.ctro.2026.101289_bb0135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41416-024-02805-5","article-title":"Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial","volume":"131","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0140","article-title":"Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial","volume":"24","author":"Chen","year":"2026","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12916-026-04781-4","article-title":"Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT)","volume":"24","author":"Chen","year":"2026","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0150","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.21037\/jtd-24-1279","article-title":"Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study","volume":"16","author":"Cheng","year":"2024","journal-title":"J. Thorac. Dis."},{"issue":"8","key":"10.1016\/j.ctro.2026.101289_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04099-9","article-title":"Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma","volume":"74","author":"Deng","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ctro.2026.101289_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.849984","article-title":"Neoadjuvant pembrolizumab and chemotherapy in Resectable Esophageal Cancer: an open-label, single-arm study (PEN-ICE)","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101289_bb0165","doi-asserted-by":"crossref","first-page":"478","DOI":"10.21037\/jgo-22-131","article-title":"Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)","volume":"13","author":"Gao","year":"2022","journal-title":"J. Gastrointest Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0170","article-title":"Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0175","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced Resectable Esophageal squamous cell carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41416-026-03349-6","article-title":"Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma","volume":"134","author":"Huang","year":"2026","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2026.101289_bb0190","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1097\/JS9.0000000000003922","article-title":"Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma","volume":"112","author":"Jin","year":"2026","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","article-title":"Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized phase II clinical trial\u202f: a randomized clinical trial of neoadjuvant therapy for ESCC","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-025-02477-4","article-title":"Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1\/2 trial (PALACE-2)","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ctro.2026.101289_bb0205","first-page":"98","article-title":"Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma","volume":"2","author":"Wang","year":"2022","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0210","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1038\/s41467-025-64660-z","article-title":"Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: phase 2 randomized trial (REVO)","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0215","article-title":"Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration","volume":"10","author":"Wu","year":"2026","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10388-025-01165-0","article-title":"Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)","volume":"23","author":"Hong","year":"2026","journal-title":"Esophagus"},{"key":"10.1016\/j.ctro.2026.101289_bb0235","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241231610","article-title":"Neoadjuvant PD-1 plus chemotherapy for locally advanced Esophageal squamous cell carcinoma","volume":"23","author":"Qian","year":"2024","journal-title":"Technol. Cancer Res. Treat"},{"issue":"6","key":"10.1016\/j.ctro.2026.101289_bb0240","doi-asserted-by":"crossref","first-page":"573","DOI":"10.17219\/acem\/170265","article-title":"Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: a prospective, single-arm, open-label study","volume":"33","author":"Wang","year":"2024","journal-title":"Adv. Clin. Exp. Med."},{"issue":"7","key":"10.1016\/j.ctro.2026.101289_bb0245","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/ijc.35261","article-title":"Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: a prospective, two-cohort, phase 2 trial","volume":"156","author":"Wang","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"21","key":"10.1016\/j.ctro.2026.101289_bb0250","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.21037\/atm-21-5381","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0255","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/cac2.12604","article-title":"Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0260","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/1078-0432.CCR-25-2367","article-title":"PET\/CT-guided neoadjuvant tislelizumab plus chemotherapy\/chemoradiotherapy for Resectable Esophageal squamous cell carcinoma: RATIONALE-213 final analysis","volume":"32","author":"Yang","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0265","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ijrobp.2023.12.033","article-title":"A phase 1b clinical trial of neoadjuvant radio-immunotherapy for Esophageal squamous cell Cancer","volume":"119","author":"Li","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.ctro.2026.101289_bb0270","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doad073","article-title":"Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma","volume":"37","author":"Zhang","year":"2024","journal-title":"Dis. Esophagus"},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0275","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.21037\/jtd-2025-215","article-title":"Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma","volume":"17","author":"Wang","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctro.2026.101289_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of chemotherapy and Toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer\u2014a phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ctro.2026.101289_bb0285","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1245\/s10434-023-13467-7","article-title":"Early and persistent dysphagia relief predicts tumor response in Esophageal squamous cell carcinoma patients treated with immunochemotherapy","volume":"30","author":"Huang","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482005","article-title":"Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0295","doi-asserted-by":"crossref","first-page":"841","DOI":"10.21037\/jgo-24-295","article-title":"Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials","volume":"15","author":"Shen","year":"2024","journal-title":"J. Gastrointest Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0300","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0305","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JS9.0000000000000978","article-title":"Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)","volume":"110","author":"Yang","year":"2024","journal-title":"Int. J. Surg."},{"issue":"11","key":"10.1016\/j.ctro.2026.101289_bb0310","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.21037\/jtd-23-1408","article-title":"Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study","volume":"15","author":"Zhang","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctro.2026.101289_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104515","article-title":"Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial","volume":"90","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-14686-9","article-title":"Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma","volume":"25","author":"Mao","year":"2025","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ctro.2026.101289_bb0325","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","article-title":"A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial","volume":"42","author":"Shang","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0330","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.ctro.2026.101289_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102579","article-title":"Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"71","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"16_suppl","key":"10.1016\/j.ctro.2026.101289_bb0340","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2025.43.16_suppl.4066","article-title":"Sequential chemo-immunotherapy as a novel bridging strategy for non-complete responders after neoadjuvant chemoradiotherapy in esophageal cancer: first prospective phase 2 trial challenging the immediate-surgery paradigm","volume":"43","author":"Peng","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctro.2026.101289_bb0345","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.21037\/jtd-24-1141","article-title":"Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study","volume":"16","author":"Sheng","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctro.2026.101289_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110797","article-title":"Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): a single-arm, bicentric, phase 2 trial","volume":"206","author":"Yang","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.ctro.2026.101289_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008631","article-title":"Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer","volume":"12","author":"Xu","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctro.2026.101289_bb0360","doi-asserted-by":"crossref","first-page":"e16116","DOI":"10.1200\/JCO.2024.42.16_suppl.e16116","article-title":"Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): preliminary results of a single-arm, open-label phase Ib trial (CRIS)","volume":"42","author":"Jiang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and Esophageal Cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ctro.2026.101289_bb0370","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-023-02354-w","article-title":"Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs","volume":"18","author":"Tseng","year":"2023","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2018.12.002","article-title":"The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy","volume":"133","author":"Deng","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","author":"Paganetti","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctro.2026.101289_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1879335","article-title":"Associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes in patients with advanced esophageal cancer","volume":"17","author":"Cai","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctro.2026.101289_bb0390","article-title":"Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)","volume":"17","author":"Zheng","year":"2026","journal-title":"Front. Immunol."}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:06:48Z","timestamp":1793354808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":78,"alternative-id":["S2405630826001849"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101289","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101289"}}